Nucl Med Commun 2021 Mar 18. Epub 2021 Mar 18.
Nuclear Medicine Unit, ARNAS Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy Division of Cancer Sciences, University of Manchester Clinical Oncology Department, Christie NHS Foundation Trust, Manchester, UK Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina Department of Biomedicine and Prevention, University Tor Vergata, Rome Nuclear Medicine Section, IRCCS Neuromed, Pozzilli, Italy Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben, Basel, Switzerland Department of Nuclear Medicine, E.O. Ospedali Galliera, Genoa Unit of Nuclear Medicine, Fondazione Istituto G.Giglio, Cefalù Nuclear Medicine Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Aim: 18F-Fluorodeoxyglucose (FDG) PET imaging may play an important role in the restaging of patients with small-cell lung cancer (SCLC),, nevertheless, a systematic review of literature was still missing in this setting. The aim of this review was to summarize the evidence on literature regarding the utility of 18F-FDG PET imaging in restaging patients with SCLC.
Methods: A literature search was performed to retrieve original studies using 18F-FDG PET or 18F-FDG PET/computed tomography (CT) in a minimum of 10 patients with SCLC at restaging. Read More